<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240130111001&amp;v=2.18.0&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240130111001&amp;v=2.18.0&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Tue, 30 Jan 2024 16:10:02 +0000</lastbuilddate>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Deceased donor organ retrieval: impact on cardiovascular research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 29:ehae033. doi: 10.1093/eurheartj/ehae033. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38285900</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae033>10.1093/eurheartj/ehae033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285900</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Patrícia Afonso Mendes</dc:creator>
<dc:creator>Cristiane Pais Macedo</dc:creator>
<dc:creator>Sónia Moreira</dc:creator>
<dc:creator>Rogério Ferreira</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deceased donor organ retrieval: impact on cardiovascular research</dc:title>
<dc:identifier>pmid:38285900</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae033</dc:identifier>
</item>
<item>
<title>Palpitations and Recurrent Syncope in a Young Woman</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 30;149(5):402-405. doi: 10.1161/CIRCULATIONAHA.123.067865. Epub 2024 Jan 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38285741</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067865>10.1161/CIRCULATIONAHA.123.067865</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285741</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Sun Yong Lee</dc:creator>
<dc:creator>Byron K Lee</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Palpitations and Recurrent Syncope in a Young Woman</dc:title>
<dc:identifier>pmid:38285741</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067865</dc:identifier>
</item>
<item>
<title>The Future of Pediatric and Adult Heart Transplantation: Perspective From the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285740/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 30;149(5):339-341. doi: 10.1161/CIRCULATIONAHA.123.065450. Epub 2024 Jan 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285740/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38285740</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065450>10.1161/CIRCULATIONAHA.123.065450</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285740</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Emile Bacha</dc:creator>
<dc:creator>Maryjane Farr</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Future of Pediatric and Adult Heart Transplantation: Perspective From the United States</dc:title>
<dc:identifier>pmid:38285740</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065450</dc:identifier>
</item>
<item>
<title>LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 30;149(5):363-366. doi: 10.1161/CIRCULATIONAHA.123.067241. Epub 2024 Jan 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38285739</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067241>10.1161/CIRCULATIONAHA.123.067241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285739</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Raul D Santos</dc:creator>
<dc:creator>Marina Cuchel</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes</dc:title>
<dc:identifier>pmid:38285739</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067241</dc:identifier>
</item>
<item>
<title>Trajectories of Sleep Over Midlife and Incident Cardiovascular Disease Events in the Study of Women's Health Across the Nation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38284249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>CONCLUSIONS: Insomnia symptoms, when persistent over midlife or occurring with short sleep, are associated with higher CVD risk among women.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 29. doi: 10.1161/CIRCULATIONAHA.123.066491. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Up to 50% of women report sleep problems in midlife, and cardiovascular disease (CVD) is the leading cause of death in women. How chronic poor sleep exposure over decades of midlife is related to CVD risk in women is poorly understood. We tested whether trajectories of insomnia symptoms or sleep duration over midlife were related to subsequent CVD events among SWAN (Study of Women's Health Across the Nation) participants, whose sleep was assessed up to 16 times over 22 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: At baseline, SWAN participants (n=2964) were 42 to 52 years of age, premenopausal or early perimenopausal, not using hormone therapy, and free of CVD. They completed up to 16 visits, including questionnaires assessing insomnia symptoms (trouble falling asleep, waking up several times a night, or waking earlier than planned ≥3 times/week classified as insomnia), typical daily sleep duration, vasomotor symptoms, and depressive symptoms; anthropometric measurements; phlebotomy; and CVD event ascertainment (ie, fatal or nonfatal myocardial infarction, stroke, heart failure, revascularization). Sleep trajectories (ie, insomnia, sleep duration) were determined by means of group-based trajectory modeling. Sleep trajectories were tested in relation to CVD in Cox proportional hazards models (multivariable models: site, age, race and ethnicity, education, CVD risk factors averaged over visits; additional covariates: vasomotor symptoms, snoring, depression).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Four trajectories of insomnia symptoms emerged: low insomnia symptoms (n=1142 [39% of women]), moderate insomnia symptoms decreasing over time (n=564 [19%]), low insomnia symptoms increasing over time (n=590 [20%]), and high insomnia symptoms that persisted (n=668 [23%]). Women with persistently high insomnia symptoms had higher CVD risk (hazard ratio, 1.71 [95% CI, 1.19, 2.46], <i>P</i>=0.004, versus low insomnia; multivariable). Three trajectories of sleep duration emerged: persistently short (~5 hours: n=363 [15%]), moderate (~6 hours: n=1394 [55%]), and moderate to long (~8 hours: n=760 [30%]). Women with persistent short sleep had marginally higher CVD risk (hazard ratio, 1.51 [95% CI, 0.98, 2.33], <i>P</i>=0.06, versus moderate; multivariable). Women who had both persistent high insomnia and short sleep had significantly elevated CVD risk (hazard ratio, 1.75 [95% CI, 1.03, 2.98], <i>P</i>=0.04, versus low insomnia and moderate or moderate to long sleep duration; multivariable). Relations of insomnia to CVD persisted when adjusting for vasomotor symptoms, snoring, or depression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Insomnia symptoms, when persistent over midlife or occurring with short sleep, are associated with higher CVD risk among women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38284249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38284249</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066491>10.1161/CIRCULATIONAHA.123.066491</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38284249</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Rebecca C Thurston</dc:creator>
<dc:creator>Yuefang Chang</dc:creator>
<dc:creator>Christopher E Kline</dc:creator>
<dc:creator>Leslie M Swanson</dc:creator>
<dc:creator>Samar R El Khoudary</dc:creator>
<dc:creator>Elizabeth A Jackson</dc:creator>
<dc:creator>Carol A Derby</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Trajectories of Sleep Over Midlife and Incident Cardiovascular Disease Events in the Study of Women's Health Across the Nation</dc:title>
<dc:identifier>pmid:38284249</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066491</dc:identifier>
</item>
<item>
<title>A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38282532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>CONCLUSIONS: A model which accurately predicts LV recovery at 6 months in women with PPCM was derived. The corresponding ESC EORP PPCM Recovery Score can be easily applied in clinical practice to predict the probability of LV recovery for an individual in order to guide tailored counselling and treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 29:ehad888. doi: 10.1093/eurheartj/ehad888. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: There are no established clinical tools to predict left ventricular (LV) recovery in women with peripartum cardiomyopathy (PPCM). Using data from women enrolled in the ESC EORP PPCM Registry, the aim was to derive a prognostic model to predict LV recovery at 6 months and develop the 'ESC EORP PPCM Recovery Score'-a tool for clinicians to estimate the probability of LV recovery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From 2012 to 2018, 752 women from 51 countries were enrolled. Eligibility included (i) a peripartum state, (ii) signs or symptoms of heart failure, (iii) LV ejection fraction (LVEF) ≤ 45%, and (iv) exclusion of alternative causes of heart failure. The model was derived using data from participants in the Registry and internally validated using bootstrap methods. The outcome was LV recovery (LVEF ≥50%) at six months. An integer score was created.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 465 women had a 6-month echocardiogram. LV recovery occurred in 216 (46.5%). The final model included baseline LVEF, baseline LV end diastolic diameter, human development index (a summary measure of a country's social and economic development), duration of symptoms, QRS duration and pre-eclampsia. The model was well-calibrated and had good discriminatory ability (C-statistic 0.79, 95% confidence interval [CI] 0.74-0.83). The model was internally validated (optimism-corrected C-statistic 0.78, 95% CI 0.73-0.82).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A model which accurately predicts LV recovery at 6 months in women with PPCM was derived. The corresponding ESC EORP PPCM Recovery Score can be easily applied in clinical practice to predict the probability of LV recovery for an individual in order to guide tailored counselling and treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38282532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38282532</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad888>10.1093/eurheartj/ehad888</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38282532</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Alice M Jackson</dc:creator>
<dc:creator>Sorel Goland</dc:creator>
<dc:creator>Hasan Ali Farhan</dc:creator>
<dc:creator>Israa Fadhil Yaseen</dc:creator>
<dc:creator>Hawani Sasmaya Prameswari</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry</dc:title>
<dc:identifier>pmid:38282532</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad888</dc:identifier>
</item>
<item>
<title>Gut-liver axis calibrates intestinal stem cell fitness</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38280375/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>The gut and liver are recognized to mutually communicate through the biliary tract, portal vein, and systemic circulation. However, it remains unclear how this gut-liver axis regulates intestinal physiology. Through hepatectomy and transcriptomic and proteomic profiling, we identified pigment epithelium-derived factor (PEDF), a liver-derived soluble Wnt inhibitor, which restrains intestinal stem cell (ISC) hyperproliferation to maintain gut homeostasis by suppressing the Wnt/β-catenin signaling...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 22:S0092-8674(24)00003-5. doi: 10.1016/j.cell.2024.01.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The gut and liver are recognized to mutually communicate through the biliary tract, portal vein, and systemic circulation. However, it remains unclear how this gut-liver axis regulates intestinal physiology. Through hepatectomy and transcriptomic and proteomic profiling, we identified pigment epithelium-derived factor (PEDF), a liver-derived soluble Wnt inhibitor, which restrains intestinal stem cell (ISC) hyperproliferation to maintain gut homeostasis by suppressing the Wnt/β-catenin signaling pathway. Furthermore, we found that microbial danger signals resulting from intestinal inflammation can be sensed by the liver, leading to the repression of PEDF production through peroxisome proliferator-activated receptor-α (PPARα). This repression liberates ISC proliferation to accelerate tissue repair in the gut. Additionally, treating mice with fenofibrate, a clinical PPARα agonist used for hypolipidemia, enhances colitis susceptibility due to PEDF activity. Therefore, we have identified a distinct role for PEDF in calibrating ISC expansion for intestinal homeostasis through reciprocal interactions between the gut and liver.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38280375/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38280375</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.001>10.1016/j.cell.2024.01.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38280375</guid>
<pubDate>Sat, 27 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Girak Kim</dc:creator>
<dc:creator>Zuojia Chen</dc:creator>
<dc:creator>Jian Li</dc:creator>
<dc:creator>Jialie Luo</dc:creator>
<dc:creator>Felipe Castro-Martinez</dc:creator>
<dc:creator>Jan Wisniewski</dc:creator>
<dc:creator>Kairong Cui</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Jialei Sun</dc:creator>
<dc:creator>Xiaobai Ren</dc:creator>
<dc:creator>Susan E Crawford</dc:creator>
<dc:creator>S Patricia Becerra</dc:creator>
<dc:creator>Jimin Zhu</dc:creator>
<dc:creator>Taotao Liu</dc:creator>
<dc:creator>Sui Wang</dc:creator>
<dc:creator>Keji Zhao</dc:creator>
<dc:creator>Chuan Wu</dc:creator>
<dc:date>2024-01-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Gut-liver axis calibrates intestinal stem cell fitness</dc:title>
<dc:identifier>pmid:38280375</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.001</dc:identifier>
</item>
<item>
<title>Gut complement induced by the microbiota combats pathogens and spares commensals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38280374/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>Canonically, the complement system is known for its rapid response to remove microbes in the bloodstream. However, relatively little is known about a functioning complement system on intestinal mucosal surfaces. Herein, we report the local synthesis of complement component 3 (C3) in the gut, primarily by stromal cells. C3 is expressed upon commensal colonization and is regulated by the composition of the microbiota in healthy humans and mice, leading to an individual host's specific luminal C3...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 22:S0092-8674(24)00001-1. doi: 10.1016/j.cell.2023.12.036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Canonically, the complement system is known for its rapid response to remove microbes in the bloodstream. However, relatively little is known about a functioning complement system on intestinal mucosal surfaces. Herein, we report the local synthesis of complement component 3 (C3) in the gut, primarily by stromal cells. C3 is expressed upon commensal colonization and is regulated by the composition of the microbiota in healthy humans and mice, leading to an individual host's specific luminal C3 levels. The absence of membrane attack complex (MAC) components in the gut ensures that C3 deposition does not result in the lysis of commensals. Pathogen infection triggers the immune system to recruit neutrophils to the infection site for pathogen clearance. Basal C3 levels directly correlate with protection against enteric infection. Our study reveals the gut complement system as an innate immune mechanism acting as a vigilant sentinel that combats pathogens and spares commensals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38280374/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38280374</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.12.036>10.1016/j.cell.2023.12.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38280374</guid>
<pubDate>Sat, 27 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Meng Wu</dc:creator>
<dc:creator>Wen Zheng</dc:creator>
<dc:creator>Xinyang Song</dc:creator>
<dc:creator>Bin Bao</dc:creator>
<dc:creator>Yuanyou Wang</dc:creator>
<dc:creator>Deepshika Ramanan</dc:creator>
<dc:creator>Daping Yang</dc:creator>
<dc:creator>Rui Liu</dc:creator>
<dc:creator>John C Macbeth</dc:creator>
<dc:creator>Elyza A Do</dc:creator>
<dc:creator>Warrison A Andrade</dc:creator>
<dc:creator>Tiandi Yang</dc:creator>
<dc:creator>Hyoung-Soo Cho</dc:creator>
<dc:creator>Francesca S Gazzaniga</dc:creator>
<dc:creator>Marit Ilves</dc:creator>
<dc:creator>Daniela Coronado</dc:creator>
<dc:creator>Charlotte Thompson</dc:creator>
<dc:creator>Saiyu Hang</dc:creator>
<dc:creator>Isaac M Chiu</dc:creator>
<dc:creator>Jeffrey R Moffitt</dc:creator>
<dc:creator>Ansel Hsiao</dc:creator>
<dc:creator>John J Mekalanos</dc:creator>
<dc:creator>Christophe Benoist</dc:creator>
<dc:creator>Dennis L Kasper</dc:creator>
<dc:date>2024-01-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Gut complement induced by the microbiota combats pathogens and spares commensals</dc:title>
<dc:identifier>pmid:38280374</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.12.036</dc:identifier>
</item>
<item>
<title>Focus on vascular biology: new therapeutic targets in atherosclerosis, aortic dissection, and peripheral artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38279935/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 27;45(4):239-242. doi: 10.1093/eurheartj/ehae004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38279935/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38279935</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae004>10.1093/eurheartj/ehae004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38279935</guid>
<pubDate>Sat, 27 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-01-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on vascular biology: new therapeutic targets in atherosclerosis, aortic dissection, and peripheral artery disease</dc:title>
<dc:identifier>pmid:38279935</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae004</dc:identifier>
</item>
<item>
<title>Reply to 'Graded exercise therapy should not be recommended for patients with post-exertional malaise'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38279048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 26. doi: 10.1038/s41569-024-00994-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38279048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38279048</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00994-3>10.1038/s41569-024-00994-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38279048</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Artur Fedorowski</dc:creator>
<dc:creator>Alessandra Fanciulli</dc:creator>
<dc:creator>Satish R Raj</dc:creator>
<dc:creator>Robert Sheldon</dc:creator>
<dc:creator>Cyndya A Shibao</dc:creator>
<dc:creator>Richard Sutton</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Reply to 'Graded exercise therapy should not be recommended for patients with post-exertional malaise'</dc:title>
<dc:identifier>pmid:38279048</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00994-3</dc:identifier>
</item>
<item>
<title>Graded exercise therapy should not be recommended for patients with post-exertional malaise</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38279047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 26. doi: 10.1038/s41569-024-00992-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38279047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38279047</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00992-5>10.1038/s41569-024-00992-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38279047</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Femke Christina Ching-Chuan van Rhijn-Brouwer</dc:creator>
<dc:creator>Merel Hellemons</dc:creator>
<dc:creator>Michael Stingl</dc:creator>
<dc:creator>Kathryn Hoffmann</dc:creator>
<dc:creator>Joanne VanDerNagel</dc:creator>
<dc:creator>Todd E Davenport</dc:creator>
<dc:creator>Eva Untersmayr</dc:creator>
<dc:creator>Carmen Scheibenbogen</dc:creator>
<dc:creator>David Putrino</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Graded exercise therapy should not be recommended for patients with post-exertional malaise</dc:title>
<dc:identifier>pmid:38279047</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00992-5</dc:identifier>
</item>
<item>
<title>Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38279046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>Immune checkpoint molecules are physiological regulators of the adaptive immune response. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death protein 1 or cytotoxic T lymphocyte-associated protein 4, have revolutionized cancer treatment and their clinical use is increasing. However, ICIs can cause various immune-related adverse events, including acute and chronic cardiotoxicity. Of these cardiovascular complications, ICI-induced acute fulminant...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 26. doi: 10.1038/s41569-023-00986-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Immune checkpoint molecules are physiological regulators of the adaptive immune response. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death protein 1 or cytotoxic T lymphocyte-associated protein 4, have revolutionized cancer treatment and their clinical use is increasing. However, ICIs can cause various immune-related adverse events, including acute and chronic cardiotoxicity. Of these cardiovascular complications, ICI-induced acute fulminant myocarditis is the most studied, although emerging clinical and preclinical data are uncovering the importance of other ICI-related chronic cardiovascular complications, such as accelerated atherosclerosis and non-myocarditis-related heart failure. These complications could be more difficult to diagnose, given that they might only be present alongside other comorbidities. The occurrence of these complications suggests a potential role of immune checkpoint molecules in maintaining cardiovascular homeostasis, and disruption of physiological immune checkpoint signalling might thus lead to cardiac pathologies, including heart failure. Although inflammation is a long-known contributor to the development of heart failure, the therapeutic targeting of pro-inflammatory pathways has not been successful thus far. The increasingly recognized role of immune checkpoint molecules in the failing heart highlights their potential use as immunotherapeutic targets for heart failure. In this Review, we summarize the available data on ICI-induced cardiac dysfunction and heart failure, and discuss how immune checkpoint signalling is altered in the failing heart. Furthermore, we describe how pharmacological targeting of immune checkpoints could be used to treat heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38279046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38279046</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00986-9>10.1038/s41569-023-00986-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38279046</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Tamás G Gergely</dc:creator>
<dc:creator>Zsófia D Drobni</dc:creator>
<dc:creator>Marinos Kallikourdis</dc:creator>
<dc:creator>Han Zhu</dc:creator>
<dc:creator>Wouter C Meijers</dc:creator>
<dc:creator>Tomas G Neilan</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Péter Ferdinandy</dc:creator>
<dc:creator>Zoltán V Varga</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure</dc:title>
<dc:identifier>pmid:38279046</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00986-9</dc:identifier>
</item>
<item>
<title>Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38275112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>CONCLUSIONS: Cardiomyocyte PKA is a master regulator of physiological CH and PaCH through regulating protein synthesis and degradation. cPKAi can be a novel approach to treat PaCH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 26. doi: 10.1161/CIRCRESAHA.123.322729. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The sympathoadrenergic system and its major effector PKA (protein kinase A) are activated to maintain cardiac output coping with physiological or pathological stressors. If and how PKA plays a role in physiological cardiac hypertrophy (CH) and pathological CH (PaCH) are not clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Transgenic mouse models expressing a PKA inhibition peptide-GFP fusion protein in a cardiac-specific and inducible manner (cPKAi) were used to determine the roles of PKA in physiological CH during postnatal growth or induced by swimming, and in PaCH induced by transaortic constriction (TAC) or augmented Ca<sup>2+</sup> influx. Kinase profiling was used to determine cPKAi specificity. Echocardiography was used to determine cardiac morphology and function. Western blotting and immunostaining were used to measure protein abundance and phosphorylation. Protein synthesis was assessed by puromycin incorporation and protein degradation by measuring protein ubiquitination and proteasome activity. Neonatal rat cardiomyocytes (NRCMs) infected with AdGFP or AdPKAi-GFP were used to determine the effects and mechanisms of cPKAi on myocyte hypertrophy. rAAV9.PKA inhibition peptide-GFP was used to treat TAC mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: (1) cPKAi delayed postnatal cardiac growth and blunted exercise-induced physiological CH; (2) PKA was activated in hearts after TAC due to activated sympathoadrenergic system, the loss of endogenous PKIα (PKA inhibitory peptide α), and the stimulation by noncanonical PKA activators; (3) cPKAi ameliorated PaCH induced by TAC and increased Ca<sup>2+</sup> influxes and blunted neonatal rat cardiomyocyte hypertrophy by isoproterenol and phenylephrine; (4) cPKAi prevented TAC-induced protein synthesis by inhibiting mTOR signaling through reducing Akt activity, but enhancing inhibitory GSK-3α and GSK-3β signals; (5) cPKAi reduced protein degradation by the ubiquitin-proteasome system via decreasing RPN6 phosphorylation; (6) cPKAi increased the expression of antihypertrophic ANP; (7) cPKAi ameliorated established PaCH and improved animal survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Cardiomyocyte PKA is a master regulator of physiological CH and PaCH through regulating protein synthesis and degradation. cPKAi can be a novel approach to treat PaCH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38275112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38275112</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322729>10.1161/CIRCRESAHA.123.322729</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38275112</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yingyu Bai</dc:creator>
<dc:creator>Xiaoying Zhang</dc:creator>
<dc:creator>Ying Li</dc:creator>
<dc:creator>Fei Qi</dc:creator>
<dc:creator>Chong Liu</dc:creator>
<dc:creator>Xiaojie Ai</dc:creator>
<dc:creator>Mingxin Tang</dc:creator>
<dc:creator>Christopher Szeto</dc:creator>
<dc:creator>Erhe Gao</dc:creator>
<dc:creator>Xiang Hua</dc:creator>
<dc:creator>Mingxing Xie</dc:creator>
<dc:creator>Xuejun Wang</dc:creator>
<dc:creator>Ying Tian</dc:creator>
<dc:creator>Yongjie Chen</dc:creator>
<dc:creator>Guowei Huang</dc:creator>
<dc:creator>Junping Zhang</dc:creator>
<dc:creator>Weidong Xiao</dc:creator>
<dc:creator>Lili Zhang</dc:creator>
<dc:creator>Xueyuan Liu</dc:creator>
<dc:creator>Qing Yang</dc:creator>
<dc:creator>Steven R Houser</dc:creator>
<dc:creator>Xiongwen Chen</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:38275112</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322729</dc:identifier>
</item>
<item>
<title>Myocardial Scar and Remodelling Predict Long-Term Mortality in Severe Aortic Stenosis Beyond 10 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38271583/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae067. doi: 10.1093/eurheartj/ehae067. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38271583/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38271583</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae067>10.1093/eurheartj/ehae067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38271583</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>George D Thornton</dc:creator>
<dc:creator>Vassilios S Vassiliou</dc:creator>
<dc:creator>Tarique A Musa</dc:creator>
<dc:creator>Nikoo Aziminia</dc:creator>
<dc:creator>Neil Craig</dc:creator>
<dc:creator>Abhishek Dattani</dc:creator>
<dc:creator>Rhodri H Davies</dc:creator>
<dc:creator>Gabriella Captur</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Saul G Myerson</dc:creator>
<dc:creator>Sanjay K Prasad</dc:creator>
<dc:creator>Gerry P McCann</dc:creator>
<dc:creator>BSCMR AS700 Consortium</dc:creator>
<dc:creator>John P Greenwood</dc:creator>
<dc:creator>Anvesha Singh</dc:creator>
<dc:creator>Thomas A Treibel</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocardial Scar and Remodelling Predict Long-Term Mortality in Severe Aortic Stenosis Beyond 10 Years</dc:title>
<dc:identifier>pmid:38271583</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae067</dc:identifier>
</item>
<item>
<title>'Training' of innate immunity following myocardial infarction exacerbates atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38271239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae024. doi: 10.1093/eurheartj/ehae024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38271239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38271239</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae024>10.1093/eurheartj/ehae024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38271239</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Niranjana Natarajan</dc:creator>
<dc:creator>Partha Dutta</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>'Training' of innate immunity following myocardial infarction exacerbates atherosclerosis</dc:title>
<dc:identifier>pmid:38271239</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae024</dc:identifier>
</item>
<item>
<title>Pre-operative withdrawal of renin-angiotensin inhibitors: time to re-visit current guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38271231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehad719. doi: 10.1093/eurheartj/ehad719. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38271231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38271231</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad719>10.1093/eurheartj/ehad719</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38271231</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>W Scott Beattie</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pre-operative withdrawal of renin-angiotensin inhibitors: time to re-visit current guidelines</dc:title>
<dc:identifier>pmid:38271231</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad719</dc:identifier>
</item>
<item>
<title>A collateral channel from the bronchial artery in chronic total occlusion of proximal right coronary artery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270256/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae036. doi: 10.1093/eurheartj/ehae036. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270256/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38270256</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae036>10.1093/eurheartj/ehae036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270256</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kosuke Tsuda</dc:creator>
<dc:creator>Wataru Nagamatsu</dc:creator>
<dc:creator>Isao Morii</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A collateral channel from the bronchial artery in chronic total occlusion of proximal right coronary artery</dc:title>
<dc:identifier>pmid:38270256</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae036</dc:identifier>
</item>
<item>
<title>Critical 11 min in contrast-enhanced computed tomography for acute aortic dissection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270254/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae037. doi: 10.1093/eurheartj/ehae037. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270254/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38270254</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae037>10.1093/eurheartj/ehae037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270254</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yusuke Iguchi</dc:creator>
<dc:creator>Arudo Hiraoka</dc:creator>
<dc:creator>Genta Chikazawa</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Critical 11 min in contrast-enhanced computed tomography for acute aortic dissection</dc:title>
<dc:identifier>pmid:38270254</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae037</dc:identifier>
</item>
<item>
<title>Increasing cardiovascular hospitalization rates among young and middle-aged adults in the USA suggest a need for multi-faceted solutions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae027. doi: 10.1093/eurheartj/ehae027. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38270197</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae027>10.1093/eurheartj/ehae027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270197</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Samantha T Harris</dc:creator>
<dc:creator>Karen E Joynt Maddox</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Increasing cardiovascular hospitalization rates among young and middle-aged adults in the USA suggest a need for multi-faceted solutions</dc:title>
<dc:identifier>pmid:38270197</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae027</dc:identifier>
</item>
<item>
<title>Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>CONCLUSIONS: Transcatheter aortic valve replacement can be performed safely in patients with untreated chronic obstructive CAD, without portending higher procedural complication rates and with relatively low rates of unplanned coronary revascularization and acute coronary syndrome at 1 year.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae019. doi: 10.1093/eurheartj/ehae019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In transcatheter aortic valve replacement (TAVR) recipients, the optimal management of concomitant chronic obstructive coronary artery disease (CAD) remains unknown. Some advocate for pre-TAVR percutaneous coronary intervention, while others manage it expectantly. The aim of this study was to assess the impact of varying degrees and extent of untreated chronic obstructive CAD on TAVR and longer-term outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors conducted a retrospective cohort study of TAVR recipients from January 2015 to November 2021, separating patients into stable non-obstructive or varying degrees of obstructive CAD. The major outcomes of interest were procedural all-cause mortality and complications, major adverse cardiovascular events, and post-TAVR unplanned coronary revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 1911 patients meeting inclusion, 75%, 6%, 10%, and 9% had non-obstructive, intermediate-risk, high-risk, and extreme-risk CAD, respectively. Procedural complication rates overall were low (death 0.4%, shock 0.1%, extracorporeal membrane oxygenation 0.1%), with no difference across groups. At a median follow-up of 21 months, rates of acute coronary syndrome and unplanned coronary revascularization were 0.7% and 0.5%, respectively, in the non-obstructive population, rising in incidence with increasing severity of CAD (P &lt; .001 for acute coronary syndrome/unplanned coronary revascularization). Multivariable analysis did not yield a significantly greater risk of all-cause mortality or major adverse cardiovascular events across groups. One-year acute coronary syndrome and unplanned coronary revascularization rates in time-to-event analyses were significantly greater in the non-obstructive (98%) vs. obstructive (94%) subsets (Plog-rank&lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Transcatheter aortic valve replacement can be performed safely in patients with untreated chronic obstructive CAD, without portending higher procedural complication rates and with relatively low rates of unplanned coronary revascularization and acute coronary syndrome at 1 year.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38270189</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae019>10.1093/eurheartj/ehae019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270189</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ian Persits</dc:creator>
<dc:creator>Habib Layoun</dc:creator>
<dc:creator>Nicholas P Kondoleon</dc:creator>
<dc:creator>Nikolaos Spilias</dc:creator>
<dc:creator>Osamah Badwan</dc:creator>
<dc:creator>Joseph Sipko</dc:creator>
<dc:creator>James J Yun</dc:creator>
<dc:creator>Ankur Kalra</dc:creator>
<dc:creator>Iryna Dykun</dc:creator>
<dc:creator>Larisa G Tereshchenko</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:creator>Grant W Reed</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Rishi Puri</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement</dc:title>
<dc:identifier>pmid:38270189</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae019</dc:identifier>
</item>
<item>
<title>Deciphering connections: how is cryoablation interlinking with disease progression in atrial fibrillation ablation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240130111001&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 24:ehad872. doi: 10.1093/eurheartj/ehad872. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240130111001&v=2.18.0">38267267</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad872>10.1093/eurheartj/ehad872</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267267</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Hadi Younes</dc:creator>
<dc:creator>Swati Rao</dc:creator>
<dc:creator>Nassir Marrouche</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deciphering connections: how is cryoablation interlinking with disease progression in atrial fibrillation ablation?</dc:title>
<dc:identifier>pmid:38267267</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad872</dc:identifier>
</item>





























</channel>
</rss>